| |
2 Press Briefings by White House Monkeypox Response Team and Public Health Officials
|
| |
| |
September 15, 2022
- Our data tells us that monkeypox is not an infection that exists in isolation. It travels with HIV and other sexually transmitted infections.
- An MMWR published last week tells us that 61 percent of people diagnosed with monkeypox either had HIV or an STI. We quickly used this data to change how monkeypox services can be supported by public health departments, clinics, and community-based organizations
- That’s why today, as you heard, we’re opening applications for our second equity intervention pilot that focuses on smaller projects that help us reach the communities we need to link to monkeypox vaccines, education, testing, and treatment…...We have allocated 10,000 vials - that’s up to 50,000 doses of vaccine - for these smaller equity interventions.
- cases regularly trending down - in fact, down by nearly 50 percent since its peak in early August.
- knowledge of a monkeypox vaccine has jumped from approximately a third of Americans to over 60 percent.
- As of September 14th, over 59,600 cases have been detected globally in 103 countries. In the United States, there have been nearly 23,000 cases of monkeypox identified across all 50 states, the District of Columbia, and Puerto Rico.
-Over the last several weeks, we’ve been pleased to see a decline in the growth of new cases here and abroad, though there are areas of the U.S. where the rate of rise in new cases is still increasing.
- Over the past several weeks, we have also seen the racial and ethnic makeup of this outbreak evolve. While monkeypox cases were first seen predominantly in non-Hispanic white men, in the last week, among the cases for which we have race and ethnicity data, non-Hispanic men represented 38 - non-Hispanic Black men represented 38 percent of cases, Latino or Hispanic men represented 25 percent of cases, and non-Hispanic white men represented 26 percent of cases.
- new case numbers are down nearly 50 percent since early August.
- our large event pilot has been incredibly successful: these efforts are reaching Black and brown communities, a top priority of this administration
- In the United States, we are conducting - and it has already started on September the 8th - a phase three trial of tecovirimat for monkeypox in the United States. That is referred to as the STOMP trial, standing for: the study of tecovirimat for human monkeypox virus.
- To date, over 540,000 doses of vaccine have been administered across the 39 jurisdictions reporting data. Over the past few weeks, we’ve seen an increase in second doses administered as more people have become eligible for their second dose, specifically 28 days after their first dose.
- As a reminder, JYNNEOS is a two-dose vaccine and it is important to receive the second dose in the series to have the best protection against monkeypox, which current data suggest occurs 14 days after that second dose.
- Working closely with jurisdictions to provide the most complete picture of who is getting vaccinated, we’ve been able to receive data on race and ethnicity for over 91 percent of the first doses reported. Among these first doses reported, those who are white represent about 47 percent of people who received their first dose. Those who are Hispanic represent about 21 percent. And those who are Black represent about 12 percent.
- In Georgia, nearly 70 percent of the people who were vaccinated at Black Pride identified as non-white.
- This new Monkeypox Vaccine Equity Pilot Program - So far, through this program, monkeypox vaccines have been administered to over 10,000 people at large events, including Southern Decadence in New Orleans, Atlanta Black Gay Pride, Charlotte Pride, Boise Pride Festival, and Oakland Pride and Pridefest.
https://www.whitehouse.gov/briefing-room/press-briefings/2022/09/15/press-briefing-by-white-house-monkeypox-response-team-and-public-health-officials-5/
-------------------------------------
September 07, 2022
Press Briefing by Press Secretary Karine Jean-Pierre, National Monkeypox Response Coordinator Bob Fenton and Deputy Coordinator Dr. Demetre Daskalakis
As we announced a couple of weeks back, we have ample supply to vaccinate the highest-risk individuals against monkeypox. Nearly all jurisdictions have moved toward the intradermal vaccine approach, which means that jurisdictions have effectively transitioned toward an approach that has gotten not only more shots into arms but also without sacrificing the safety and effectiveness of the JYNNEOS vaccine. In fact, over 70 percent of all vaccines being administered in the United States today are given intradermally.
Our focus now is to reach the remainder of the eligible population where they are: at trusted locations and events across the country. And equity has to be a key point and priority embedded in throughout our response.
The CDC is reporting fewer and fewer cases recently among men who - fewer and fewer cases among men who recently had sex with men: roughly 66 percent, down from 95 percent two months ago.
Fewer and fewer cases are being seen among white people and more among people of color. I think it’s something close to 75 percent now
DR. DASKALAKIS: Yeah, so I think, you know, this - this virus transmits through very close skin-to-skin physical contact, often in the setting of sexual exposure. But there are other mechanisms for its transmission, including, if you touch objects that individuals who’ve had monkeypox touch or if you have prolonged exposure to respiratory droplets.
Fewer and fewer cases are being seen among white people and more among people of color. I think it’s something close to 75 percent now.
This past week, we saw how successful that approach is. Because of our direct allocations for Southern Decadence in New Orleans, Black Pride in Atlanta, and Oakland Pride, thousands of shots were administered during these events. In fact, over 3,000 doses were administered at Southern Decadence and their affiliated events. And nearly 4,000 doses were administered at Black Pride in Atlanta.
That means thousands of individuals are being - getting their protection against monkeypox that they may not have if - otherwise.
These events demonstrate our strategy is working.
We’re also accelerating our efforts to provide vaccines to places and people that we know will make a difference. As Dr. Daskalakis announced last week, we are launching a new program that allows local health departments to request vaccines to use innovatively through strategies to reach Black and brown communities.
And today, we’re announcing that we’re providing more vaccines to upcoming Pride events across the country - first to Idaho, where 820 doses will be made available for the weekend of Boise Pride; and second, 10,000 doses to California, ahead of the Folsom Street Fair, the Castro Street Fair in San Francisco toward the end of this month.
We will continue to pull every lever and meet people where they are to end this outbreak. And we’re already seeing progress, as Dr. Daskalakis will brief out here in a little bit.
So that’s why our approach centered on increasing vaccine access, including through equity interventions and event allocations in partnership with our outreach and engagement efforts, will continue to be critical as we fight this outbreak.
https://www.whitehouse.gov/briefing-room/press-briefings/2022/09/07/press-briefing-by-press-secretary-karine-jean-pierre-national-monkeypox-response-coordinator-bob-fenton-and-deputy-coordinator-dr-demetre-daskalakis/
|
|
| |
| |
|
|
|
